Your Article Summary
See Latest ArticlesDose–volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy
Radiotherapy and Oncology, 06/26/09
Jin H et al. - The risk of TRP varied significantly, depending on radiation dose–volume parameters and patient smoking status. Further studies are needed to identify biological basis of smoking effect and methods to reduce the incidence of TRP.
Related Articles
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 73%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 72%
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Cancer Research, 10/06/09
Relevance Score: 71%
Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09
Relevance Score: 70%
African American lung cancer patients may have different response to new cancer-fighting drugs
EurekAlert, 10/08/09
Relevance Score: 70%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer
Oncogene, 12/16/09
The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival
Oncogene, 12/16/09
IMP3 expression is correlated with histologic grade of lung adenocarcinoma
Human Pathology, 12/16/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells
Cancer Chemotherapy and Pharmacology, 12/17/09
Port central venous catheters–associated bloodstream infection during outpatient-based chemotherapyTEST
Medical Oncology, 12/17/09
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiformeTEST
Journal of Neuro-Oncology, 12/17/09